Professur für Translationale Frauenheilkunde und Geburtshilfe

Influence of the Family Anamnesis of Breast or Ovarian Cancer on the pathological Complete Remission and the Prognosis in Patients with Breast Cancer after neoadjuvant Chemotherapy (2020) Gaß P, Haberle L, Hein A, Jud S, Lux MP, Hack C, Emons J, et al. Conference contribution Assessment of the additional clinical potential of X-ray dark-field imaging for breast cancer in a preclinical setup (2020) Emons J, Fasching P, Wunderle M, Heindl F, Rieger J, Horn F, Pelzer G, et al. Conference contribution Mammographic Density and Prognosis in Patients with primary Breast Cancer - Loss of Risk with increasing Age (2020) Heindl F, Fasching P, Hein A, Hack C, Heusinger K, Gaß P, Schulz-Wendtland R, et al. Conference contribution Progression-free survival and overall survival in patients with advanced her2-positive breast cancer treated with trastuzumab emtansine (T-dm1) after previous treatment with pertuzumab (2020) Michel LL, Hartkopf AD, Fasching P, Kolberg HC, Hadji P, Tesch H, Häberle L, et al. Journal article Influence of CDK4/6 inhibitors on the peripheral immune response in hormone receptor-positive breast cancer (2020) Peuker CA, Yaghobramzi S, Grunert C, Keilholz L, Hennig S, Schaper S, Brucker S, et al. Conference contribution Reduction of Serious Adverse Events (SAE) under palbociclib treatment in patients using an interactive eHealth system (2020) Schmidt M, Degenhardt T, Fasching P, Lüftner D, Müller V, Thomssen C, Schem C, et al. Journal article Characteristics and clinical outcome of breast cancer patients with asymptomatic brain metastases (2020) Laakmann E, Witzel I, Neunhöffer T, Weide R, Schmidt M, Park-Simon TW, Möbus V, et al. Journal article Trastuzumab Biosimilars in the Therapy of Breast Cancer – “Real World” Experiences from four Bavarian University Breast Centres (2020) Hester A, Gaß P, Fasching P, Kraemer AK, Ettl J, Diessner J, Woeckel A, et al. Journal article Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triplenegative breast cancer, TNBC) (PM(Cb)) for patients (pts) with highrisk early breast cancer (BC) (2020) Schneeweiss A, Moebus V, Tesch H, Klare P, Denkert C, Kast K, Hanusch C, et al. Conference contribution EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) plus nab-paclitaxel (nabPTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation (2020) Sharma P, Farooki A, Fasching P, Loi S, Peterson K, Prat A, Tripathy D, et al. Conference contribution